U.S. SEVERE ORAL MUCOSITIS MARKET ANALYSIS
Key players are focusing on inorganic strategies and fund raising, which is expected to drive the market growth during the forecast period.
The key players in the U.S. are focusing on fund raising activities for boosting research and development for the treatment of severe oral mucositis caused due to radiation and chemotherapy in the cancer patients. For instance, in September 2018, Galera Therapeutics, Inc., a company developing novel mechanism-based therapies, announced that the company secured US$ 150 million in a joint, oversubscribed Series C financing and royalty purchase agreement. The financing was led by new investor Clarus with participation from additional new investors Adage Capital Management, HBM Healthcare Investments, Nan Fung Life Sciences, RA Capital, Rock Springs Capital, and Tekla Capital Management LLC. The existing investors Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures, and Sofinnova Ventures also participated.
Key Players
Major players operating in the U.S. severe oral mucositis market are Innovation Pharmaceuticals Inc.*, Monopar Therapeutics Inc., Soligenix, Inc., Oragenics, Inc., Enzychem Lifesciences, Galera Therapeutics, Inc., Amgen, Inc., and Covis Pharma Group
U.S. Severe Oral Mucositis Market Report Snapshots
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize NowWant to Buy a Report but have a Limited Budget?
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request Discount
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India :